ReviewBritish journal of cancer2011
Oncogenic AKTivation of translation as a therapeutic target.
Review in British journal of cancer, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 44 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
44 citing papers in PubMed, 78 citations in OpenAlex.
- A phase II study of the dual mTOR inhibitor MLN0128 in patients with metastatic castration resistant prostate cancer.Investigational new drugs · 2018Trial
- Downregulation of AKT-mediated p27IBRO neuroscience reports · 2025Article
- OCT4 translationally promotes AKT signaling as an RNA-binding protein in stressed pluripotent stem cells.Stem cell research & therapy · 2025Article
- Irisin's Dual Role in Malignant Tumors and Its Potential as a Biomarker and Therapeutic Target.Drug design, development and therapy · 2025Review
- Purinergic P2X7R as a potential target for pancreatic cancer.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2023Review
- Regulation of eIF4E guides a unique translational program to control erythroid maturation.Science advances · 2022Article
- Cancers associated with human gammaherpesviruses.The FEBS journal · 2022Review
- Proteotoxic Stress as an Exploitable Vulnerability in Cells with Hyperactive AKT.International journal of molecular sciences · 2021Article
- Ganglioside GT1b increases hyaluronic acid synthase 2 via PI3K activation with TLR2 dependence in orbital fibroblasts from thyroid eye disease patients.BMB reports · 2021Article
- Echinatin suppresses esophageal cancer tumor growth and invasion through inducing AKT/mTOR-dependent autophagy and apoptosis.Cell death & disease · 2020Article
- Phosphoproteomics to Characterize Host Response During H3N2 Canine Influenza Virus Infection of Dog Lung.Frontiers in veterinary science · 2020Article
- Monitoring flux in signalling pathways through measurements of 4EBP1-mediated eIF4F complex assembly.BMC biology · 2019Article
- Revealing nascent proteomics in signaling pathways and cell differentiation.Proceedings of the National Academy of Sciences of the United States of America · 2018Article
- Significance of PI3K/AKT signaling pathway in metastasis of esophageal squamous cell carcinoma and its potential as a target for anti-metastasis therapy.Oncotarget · 2017Article
- Functional genomics reveals that tumors with activating phosphoinositide 3-kinase mutations are dependent on accelerated protein turnover.Genes & development · 2016Article
- Article
- The genetics and mechanisms of T cell acute lymphoblastic leukaemia.Nature reviews. Cancer · 2016Review
- Polysome Profiling Links Translational Control to the Radioresponse of Glioblastoma Stem-like Cells.Cancer research · 2016Article
- Signaling Pathways in Thyroid Cancer and Their Therapeutic Implications.Journal of clinical medicine research · 2016Review
- Targeting the PI3K/Akt signaling pathway in gastric carcinoma: A reality for personalized medicine?World journal of gastroenterology · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
Abstract
The AKT signalling pathway is a major regulator of protein synthesis that impinges on multiple cellular processes frequently altered in cancer, such as proliferation, cell growth, survival, and angiogenesis. AKT controls protein synthesis by regulating the multistep process of mRNA translation at every stage from ribosome biogenesis to translation initiation and elongation. Recent studies have highlighted the ability of oncogenic AKT to drive cellular transformation by altering gene expression at the translational level. Oncogenic AKT signalling leads to both global changes in protein synthesis as well as specific changes in the translation of select mRNAs. New and developing technologies are significantly advancing our ability to identify and functionally group these translationally controlled mRNAs into gene networks based on their modes of regulation. How oncogenic AKT activates ribosome biogenesis, translation initiation, and translational elongation to regulate these translational networks is an ongoing area of research. Currently, the majority of therapeutics targeting translational control are focused on blocking translation initiation through inhibition of eIF4E hyperactivity. However, it will be important to determine whether combined inhibition of ribosome biogenesis, translation initiation, and translation elongation can demonstrate improved therapeutic efficacy in tumours driven by oncogenic AKT.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.